Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Clinical Specialties Issues Voluntary Nationwide Recall of Avastin Unit Dose Syringes due to Potential Serious Eye Infection

By Pharmaceutical Processing | March 19, 2013


Clinical Specialties is voluntarily recalling Avastin unit dose syringes.

The product has or potentially could result in an infection within the eye. Clinical Specialties has received reports of five intra-ocular infections from physician’s office and this is how the problem was identified.

This product was being used solely as an off label use by an ophthalmologist for macular degeneration and is packaged in sterile syringes. The affected product name lots are as follows:

Lot Number

 

Exp. Date

 

Lot Number

 

Exp. Date

CABDAHAC:39

 

5/8/2013

 

CABDACAB:56

 

4/2/2013

CABDAGAC:58

 

4/13/2013

 

CABDACAB:76

 

4/2/2013

CABDAHAC:77

 

4/8/2013

 

CABDACAB:89

 

4/2/2013

CABDBIAC:86

 

4/19/2013

 

CABDADAB:69

 

4/3/2013

CABDCFAC:29

 

4/26/2013

 

CABDADAB:93

 

4/3/2013

CABDAEAD:26

 

5/3/2013

 

CABDADAB:54

 

4/3/2013

CABDAEAC:47

 

5/5/2013

 

CABDAEAB:96

 

4/4/2013

CABDAEAC:58

 

5/5/2013

 

CABDAHAB:00

 

4/7/2013

CABDAFAC:46

 

5/6/2013

 

CABDAHAB:59

 

4/7/2013

CABDAIAC:46

 

5/9/2013

 

CABDAHAB:18

 

4/7/2013

CABDBCAC:94

 

5/13/2013

 

CABDAJAB:30

 

4/9/2013

CABDCCAC:26

 

5/23/2013

 

CABDAJAB:70

 

4/9/2013

CABDCFAC:81

 

5/26/2013

 

CABDAJAB:97

 

4/9/2013

CABDABAD:05

 

5/30/2013

 

CABDBAAB:63

 

4/10/2013

CABDAFAC:47

 

5/6/2013

 

CABDBAAB:77

 

4/10/2013

CABDAGAC:43

 

5/7/2013

 

CABDBAAB:54

 

4/10/2013

CABDBDAC:69

 

5/14/2013

 

CABDBAAB:04

 

4/10/2013

CABDBIAC:77

 

5/19/2013

 

CABDBEAB:97

 

4/14/2013

CABDCHAC:19

 

5/28/2013

 

CABDBFAB:67

 

3/16/2013

CABDAHAD:21

 

6/5/2013

 

CABDBFAB:61

 

4/15/2013

CABDCFAC:17

 

5/26/2013

 

CABDBFAB:84

 

4/15/2013

CABDAHAD:00

 

6/5/2013

 

CABDBGAB:34

 

4/16/2013

CABDBCAC:47

 

5/13/2013

 

CABDBHAB:33

 

4/17/2013

CABDCBAC:97

 

5/22/2013

 

CABDBHAB:71

 

4/17/2013

CABDAGAC:08

 

5/7/2013

 

CABDBHAB:75

 

4/17/2013

CABDBCAC:15

 

5/13/2013

 

CABDCBAB:66

 

4/21/2013

CABDBDAC:17

 

5/14/2013

 

CABDCCAB:64

 

4/22/2013

CABDCIAC:42

 

5/29/2013

 

CABDCDAB:38

 

4/23/2013

CABDBEAC:44

 

5/15/2013

 

CABDCEAB:71

 

4/24/2013

CABDCBAC:79

 

5/22/2013

 

CABDCEAB:04

 

4/24/2013

CABDCIAC:00

 

5/29/2013

 

CABDCFAB:22

 

3/26/2013

CABDAHAD:82

 

6/5/2013

 

CABDCFAB:14

 

4/25/2013

CABDCBAC:31

 

5/22/2013

 

CABDCIAB:51

 

4/28/2013

CABDCIAB:68

 

4/28/2013

 

CABDCIAB:93

 

3/29/2013

CABDCJAB:59

 

4/29/2013

 

CABDDBAB:71

 

4/1/2013

CABDDBAB:93

 

5/1/2013

 

CABCBJBC:00

 

3/19/2013

CABCCGBC:92

 

2/24/2013

 

CABCCGBC:30

 

3/26/2013

CABCCGBC:49

 

3/26/2013

 

CABCCHBC:55

 

3/27/2013

CABCCIBC:39

 

3/23/2013

 

CABCDBBC:87

 

3/31/2013

CABCDBBC:71

 

3/1/2013

 

 

 

 

This product would be administered by a licensed physician in a surgery or physician’s office setting. The syringes were distributed to doctors’ offices in Georgia, Louisiana, South Carolina, and Indiana from December 18, 2012 to present.

Clinical Specialties has notified the physician’ offices by telephone. Doctors that have product which is being recalled should stop using the Avastin immediately.

Consumers with questions regarding this recall may contact Clinical Specialties by phone at 866.880.1915 or e-mail address at [email protected] ; Monday through Friday between the hours of 10 am to 5 pm EST. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Online: www.fda.gov/medwatch/report.htm

Regular Mail: use postage-paid, pre-addressed Form FDA 3500 available at:
www.fda.gov/MedWatch/getforms.htm. Mail to address on the pre-addressed form.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Fax: 1-800-FDA-0178

 

Related Articles Read More >

kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
Disposable syringe and American currency on black background
PBMs increasingly under fire in drug-pricing battle
Johnson & Johnson logo
Timeline: Navigating Johnson & Johnson’s talc lawsuits and their stock performance impact
pharmaceutical industry. Production line machine conveyor with glass bottles ampoules at factory
5 core trends in drug recalls: An analysis of 2022 and Q1 2023
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE